Multiple soluble and surface proteins (None)

Multiple soluble and surface proteins is a descriptive term used to categorize the broad range of molecular targets addressed by polyvalent immunotherapies, most notably intravenous immunoglobulin (IVIG) and therapeutic plasma exchange. Rather than focusing on a single receptor or enzyme, these therapies interact with a diverse array of components including inflammatory cytokines, complement proteins, pathogenic autoantibodies, and various cell surface receptors such as Fc receptors and adhesion molecules. By modulating these multiple factors simultaneously, the treatment can suppress systemic inflammation, neutralize circulating toxins or antibodies, and restore immune homeostasis. This multi-target approach is particularly effective in treating complex autoimmune and inflammatory conditions where the underlying pathology involves multiple pathways. Common indications for drugs hitting these targets include chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia (ITP), and Kawasaki disease. The interaction with soluble proteins often involves direct neutralization, while the interaction with surface proteins typically involves blocking or modulating receptor signaling. Despite the lack of specificity, these therapies are cornerstone treatments in clinical immunology due to their ability to address multifaceted disease mechanisms.

Other names

Soluble and surface-bound proteinsBroad immunomodulatory targetsPolyclonal antibody targetsNon-specific immune targets

Neutralization of autoantibodies and toxins, modulation of Fc receptor expression and affinity, inhibition of complement-mediated damage, and neutralization of inflammatory cytokines.